Alpha Radionuclide Therapy
Therapeutic applications of alpha (α)-emitting radionuclides were introduced soon after the isolation of radium from pitch blende by Marie Curie in the early twentieth century. Because of the very high linear energy transfer (LET), α-emitters can be very lethal and result in very effective cell killing sterilization if the α-decay commences at the cellular target site. With recent innovations in cancer cell targeting with antibodies and peptides and rapid targeting strategies, the efficacy of several radiopharmaceuticals to which α-emitters have been attached has been demonstrated. In particular, the effectiveness of pain management has recently demonstrated with 223Ra chloride (Xofigo®) in patients with hormone refractory skeletal metastases from prostate cancer. This chapter discusses various α-emitting radionuclides for therapy and several interesting applications.
KeywordsInternational Atomic Energy Agency Alpha Particle Linear Energy Transfer Relative Biological Effectiveness Radionuclide Therapy
- Abbas N, Heyerdahl H, Bruland OS, et al. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab. EJNMI Research. 2011. http://link.springer.com/article/10.1186/2191-219X-1-18/fulltext.html.
- Azure MT, Archer RD, Sastry KSR, et al. Biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters. Radiat Res. 1994;140:276–83.PubMedCrossRefPubMedCentralGoogle Scholar
- Friesen C, Roscher M, Hormann I, et al. Anti-CD33-antibodies labelled with the alpha emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur J Cancer. 2013;49:2542–54.PubMedCrossRefGoogle Scholar
- Hall EJ. Radiobiology for the radiologist. 4th ed. Philadelphia: JB Lippincott Company; 1994.Google Scholar
- Holden CS, Schenter RE. Production of actinium-227 and thorium-228 from radium-226 to supply alpha-emitting isotopes radium-223, thorium-227, radium-224, bismuth-212. 2014.US 20140226774. http://www.google.com/patents/US20140226774.
- IAEA Technical Report SeriEs 15. A basic toxicity classification of radionuclides. 1963. http://www.iaea.org/inis/collection/NCLCollectionStore/_Public/24/072/24072024.pdf.
- IAEA Technical Report Series 468. Cyclotron produced radioisotopes: physical characteristics and production methods. 2009. http://www-pub.iaea.org/MTCD/publications/PDF/trs468_web.pdf.
- Metzenbaum M. Radium: Its value in the treatment of lupus, rodent ulcer, and epithelioma, with reports of cases. Int Clin (JB Lippincott). 1905;4(14):21–31.Google Scholar
- Nicolini M, Mazzi U. Therapeutic potential of alpha-emitters: chemistry to biology to clinical applications. Padova: SGE Editorali; 1999.Google Scholar
- Proescher F. The intravenous injection of soluble radium salts in men. Radium. 1913;1:9–10.Google Scholar
- Sgouros G, Roeske JC, McDevitt MR, et al. SNM MIRD Committee, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, Zanzonico PB. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.Google Scholar